3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. 

This is because Novartis Pharmaceuticals did not provide an evidence submission.

Read NICE technology appraisal